Edition:
United Kingdom

Novavax Reaches Agreement With FDA On Late Stage Trial Design For Nanoflu


Monday, 5 Aug 2019 

Aug 5 (Reuters) - Novavax Inc ::NOVAVAX REACHES AGREEMENT WITH THE FDA ON PIVOTAL PHASE 3 TRIAL DESIGN FOR NANOFLU.NOVAVAX REACHES AGREEMENT WITH THE FDA ON PIVOTAL PHASE 3 TRIAL DESIGN FOR NANOFLU.NOVAVAX INC - CLINICAL TRIAL EXPECTED TO INITIATE IN FALL OF 2019.NOVAVAX INC - TOP-LINE CLINICAL DATA EXPECTED IN Q1 OF 2020.NOVAVAX INC - RECEIVED INPUT FROM U.S. FDA ON END-OF PHASE 2 QUESTIONS, REACHED AGREEMENT ON PHASE 3 TRIAL DESIGN FOR NANOFLU. 

Company Quote

6.74
-0.01 -0.15%
18 Sep 2019